A study evaluating the utility of novel imaging biomarkers (radiomics) to distinguish patients with stage 3 NSCLC may be able to predict who will benefit from treatment from those likely to progress despite therapy. This study was presented at the , which was held virtually 4-10 June, 2021 [1]. Physician’s Weekly spoke with presenter and researcher Dr. Khalid Jazieh, Cleveland Clinic, Ohio.
Article Date
June 23, 2021